THE WIRE · № 74901
De nouvelles perspectives pour la coopération internationale : Kexing Biopharm se distingue au salon CPHI Milan 2026
01 THE MACHINE READ
WHY IT MATTERS.
A Chinese pharma's conference presence signals export ambitions but carries no pricing or contract detail to move markets.
Promotional conference recap with no financial substance
Any disclosed partnership or licensing deal
Press release may overstate commercial traction
FULL DISPATCH
MILAN, 11 octobre 2026 /PRNewswire/ -- Du 6 au 8 octobre 2026, Kexing Biopharm (688136.SH) a participé au salon CPHI Milan 2026, où il a présenté son portefeuille mondial de médicaments innovants, ses biosimilaires développés en collaboration, ainsi qu'une large gamme de produits...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer2026-10-10 04:41 UTC
Oura Smart Ring Wants $2 Billion From Its IPO. Original Medicare Still Pays $0 for the Health-Tracking Gear2026-10-10 14:00 UTC
How de-extincting dire wolves and woolly mammoths may extend human life2026-10-10 14:00 UTC
Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOs2026-10-10 15:08 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.